XNAS · ANAB
-0.44% · -$0.2000 · Vol Not reported
Pre-market · updated 05:02:11 ET
AnaptysBio, Inc. Common Stock

AnaptysBio, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$45.45
Card
Relationship Map

Follow $ANAB

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ANAB by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
ANAB
AnaptysBio, Inc. Common Stock
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

54/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ANAB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ANAB catalysts
About AnaptysBio, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2017
Employees
104
Country
US

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$45.65
Last session
Day high
$45.65
Last session
Day low
$45.65
Last session
Previous close
$45.65
52W high
$70.22
-35.27% from high
52W low
$31.37
36% of range
Market cap
$1.4B
EPS
$-3.9400
Beta
0.73
Shares out
29.9M
Avg volume
563.3K
VWAP
$45.65
Last session
Price history computed in-house
1W
-6.54%
1M
-19.70%
3M
-31.54%
1Y
+42.79%
YTD
-6.25%
SMA 50 $54.64 · below
SMA 200 $56.49 · below
52W position 36%

ANAB overview

Veridion Score
54
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ANAB.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ANAB Form 4 filings
Public disclosures

Congress activity in ANAB

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ANAB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ANAB in this window.
Lobbying spend

ANAB lobbying filings, year to date.

Registered lobbying filings matched to AnaptysBio, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ANAB in this window.
Loading news for ANAB
Analyst ratings
Sovereign unlock shows live analyst consensus for ANAB.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.